Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [¹⁴C]-Poseltinib in Healthy Male Subjects
NCT02914379Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of poseltinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered and Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered. Started Sep 2016; status: completed.
02
Drugs
poseltinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02914379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914379.